Structure and Dynamics of a Site-Specific Labeled Fc Fragment with Altered Effector Functions
Antibody-drug conjugates (ADCs) are a class of biotherapeutic drugs designed as targeted therapies for the treatment of cancer. Among the challenges in generating an effective ADC is the choice of an effective conjugation site on the IgG. One common method to prepare site-specific ADCs is to enginee...
Saved in:
Main Authors: | D. Travis Gallagher (Author), Chris McCullough (Author), Robert G. Brinson (Author), Joomi Ahn (Author), John P. Marino (Author), Nazzareno Dimasi (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2019-10-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Engineered Fc-glycosylation switch to eliminate antibody effector function
by: Qun Zhou, et al.
Published: (2020) -
Building a better antibody through the Fc: advances and challenges in harnessing antibody Fc effector functions for antiviral protection
by: Bronwyn M. Gunn, et al.
Published: (2021) -
PP 8.5 - 00080 Fc-engineering of anti-HIV-1 antibodies and nanobodies to improve Fc mediated effector functions
by: A. Schriek, et al.
Published: (2022) -
Harnessing the specialised effector function of FcRγ− NK cells to control HIV-1 infection
by: R. Anderko, et al.
Published: (2019) -
Therapeutic efficacy of a potent anti-Venezuelan equine encephalitis virus antibody is contingent on Fc effector function
by: Jennifer L. Schwedler, et al.
Published: (2024)